The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Álvarez-Fernández, P Maiso, J Martín… - 2008 - digital.csic.es
[Background]: Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
[PDF][PDF] The effect of proteasome inhibitor borte-zomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Álvarez-Fernández, P Maiso… - Haematologica, 2008 - core.ac.uk
Background Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
[HTML][HTML] The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Álvarez-Fernández, P Maiso… - …, 2008 - haematologica.org
Background Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
[PDF][PDF] The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Álvarez-Fernández, P Maiso… - …, 2008 - academia.edu
Background Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
[PDF][PDF] The effect of proteasome inhibitor borte-zomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Álvarez-Fernández, P Maiso… - Haematologica, 2008 - Citeseer
Background Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Alvarez-Fernández, P Maiso… - …, 2008 - pubmed.ncbi.nlm.nih.gov
Background Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
[引用][C] The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E COLADO, S ALVAREZ-FERNANDEZ… - Haematologica …, 2008 - pascal-francis.inist.fr
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug
resistance associated with the CD34+ immature phenotype CNRS Inist Pascal-Francis CNRS …
resistance associated with the CD34+ immature phenotype CNRS Inist Pascal-Francis CNRS …
[PDF][PDF] The effect of proteasome inhibitor borte-zomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Álvarez-Fernández, P Maiso… - …, 2008 - researchgate.net
Background Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
[引用][C] The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Alvarez-Fernandez, P Maiso… - Haematologica, 2008 - cir.nii.ac.jp
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug
resistance associated with the CD34+ immature phenotype | CiNii Research CiNii 国立情報学 …
resistance associated with the CD34+ immature phenotype | CiNii Research CiNii 国立情報学 …
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
E Colado, S Alvarez-Fernández, P Maiso… - …, 2008 - europepmc.org
Background Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …